Biotech Stock Soars on Potential FDA Fast-Track

Call traders are finally taking an interest

Deputy Editor
Oct 4, 2022 at 1:58 PM
facebook twitter linkedin

The shares of Inhibrx Inc (NASDAQ:INBX) are soaring today, up 41.1% at $28.48 at last glance, after the company alluded to potentially accelerated U.S. Food & Drug Administration (FDA) approval of its treatment for rare lung disease. Jefferies noted that this is the best-case scenario for the treatment, called INBRX-101, which is being developed to treat patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency.

Wall Street has been pessimistic towards the equity prior to today, and it appears that sentiment carried over into the options pits as well. Puts have greatly outweighed calls, as the latter has been virtually nonexistent. Today, however, 1,576 calls have crossed the tape, which is 175 times the intraday average, alongside 1,466 puts -- six times what's typically seen at this point. The October 30 call is the most popular, with new positions being bought to open there. 

On the charts, today's pop has INBX trading at its highest level since January, though the stock is still down 36.3% since the start of the year. The equity is also breaking above pressure at the 200-day moving average, which kept a lid on the shares' August rally. 


It's also worth noting that short interest makes up 13.3% of the stock's available float. It would take roughly seven days to buy back these bearish bets, at Inhibrx stock's average daily pace of trading. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners